JADAS-27 — Juvenile Arthritis Disease Activity Score
Composite disease-activity score for juvenile idiopathic arthritis (Consolaro 2009). 27-joint count; sum of physician global VAS (0–10) + parent/patient global VAS (0–10) + active joint count (capped 0–10) + ESR (mm/h, transformed: (ESR−20)/10, capped 0–10). Range 0–40.
Score interpretation
→ Continue current therapy. Consider taper after sustained remission ≥6 months (per BSPAR / Wallace criteria).
→ Optimise current DMARD; treat-to-target. Reassess in 1–3 months.
→ Step up therapy: methotrexate dose review, add or switch biologic (etanercept, adalimumab, tocilizumab) per NICE TAs.
→ Urgent paediatric rheumatology review. Consider IV pulse methylprednisolone, switch biologic class, intra-articular steroids, and imaging for joint damage.
Interpretation bands for the JADAS-27. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Pindolol · Non-selective β-blocker (with intrinsic sympathomimetic activity)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Melatonin · Melatonin Receptor Agonist
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.